InjazAI

Enveda raised $311 million at a $2 billion valuation to expand clinical trials of AI-discovered, nature-derived drugs, including treatments for skin conditions and weight maintenance after stopping GLP-1s.

1 min read

Enveda Raises $311M to Advance Nature-Derived AI Drugs Into Clinical Trials

What happened?

FAQ

What is Enveda?

A biotech company that uses AI to discover and develop drug compounds derived from natural sources toward clinical trials.

How much did Enveda raise and at what valuation?

It raised $311 million, bringing its valuation to $2 billion, according to the source.

Which drugs is Enveda currently testing?

Treatments targeting skin conditions and one aimed at preserving weight loss after stopping GLP-1 drugs.

Does this matter for MENA AI and health teams?

Yes. It signals opportunities for research and investment collaboration in AI-driven biotech, particularly in Gulf states investing in digital health.

Source: TechCrunch AI

AI-assisted summary of the source above. High-confidence stories publish automatically; others wait for review. Facts that are not in the source are not added.